Funder: Alzheimer's Association

Due Dates (Anticipated): August 2026 (Letter of Intent) | September 2026 (Full application)

Funding Amounts: Up to $1,000,000 (direct + indirect) per award over 2–3 years; indirect costs capped at 10% for nonprofits, not allowed for for-profits.

Summary: Supports early-phase (Phase 1 & 2) clinical trials of novel or repurposed therapies for Alzheimer’s disease and related dementias to accelerate new treatment development.